Bipolar Disorder
|
0.740 |
Biomarker
|
disease |
BEFREE |
Alteration of specific neurotrophic factors such as glial cell line-derived neurotrophic factor and S100B may be an important feature of BD.
|
27772534 |
2017 |
Bipolar Disorder
|
0.740 |
GeneticVariation
|
disease |
BEFREE |
Higher mean serum S100B levels were associated with the risk G allele of rs3788266 in BPAD cases (P = 0.0001), unaffected relatives of BPAD cases (P < 0.0001) and unrelated controls (P < 0.0001).
|
21714070 |
2011 |
Bipolar Disorder
|
0.740 |
GeneticVariation
|
disease |
BEFREE |
Recently, associations were found between variations in the S100B gene and schizophrenia as well as bipolar affective disorder.
|
21112154 |
2011 |
Bipolar Disorder
|
0.740 |
Biomarker
|
disease |
PSYGENET |
Recently, associations were found between variations in the S100B gene and schizophrenia as well as bipolar affective disorder.
|
21112154 |
2011 |
Bipolar Disorder
|
0.740 |
Biomarker
|
disease |
PSYGENET |
Higher mean serum S100B levels were associated with the risk G allele of rs3788266 in BPAD cases (P = 0.0001), unaffected relatives of BPAD cases (P < 0.0001) and unrelated controls (P < 0.0001).
|
21714070 |
2011 |
Bipolar Disorder
|
0.740 |
Biomarker
|
disease |
PSYGENET |
These genes include GRM7, previously associated to major depression disorder and bipolar disorder, SLC6A13, in anxiety disorders, and S100B, SSTR5 and COMT in schizophrenia.
|
20398908 |
2010 |
Bipolar Disorder
|
0.740 |
Biomarker
|
disease |
PSYGENET |
Fine-mapping analyses of 21q22 have previously identified transient receptor potential gene melastatin 2 (TRPM2), which is 2 Mb upstream of S100B, as a possible BPAD susceptibility gene at 21q22.
|
17525977 |
2007 |
Bipolar Disorder
|
0.740 |
Biomarker
|
disease |
BEFREE |
Fine-mapping analyses of 21q22 have previously identified transient receptor potential gene melastatin 2 (TRPM2), which is 2 Mb upstream of S100B, as a possible BPAD susceptibility gene at 21q22.
|
17525977 |
2007 |
Bipolar Disorder
|
0.740 |
Biomarker
|
disease |
CTD_human |
Regionally specific changes in levels of cortical S100beta in bipolar 1 disorder but not schizophrenia.
|
16476148 |
2006 |
Bipolar Disorder
|
0.740 |
Biomarker
|
disease |
RGD |
Our findings reinforce the role of astroglial cells in the pathogenesis of bipolar disorder and S100B protein as a marker of bipolar mania.
|
15581912 |
2004 |
Bipolar Disorder
|
0.740 |
Biomarker
|
disease |
CTD_human |
Our findings reinforce the role of astroglial cells in the pathogenesis of bipolar disorder and S100B protein as a marker of bipolar mania.
|
15581912 |
2004 |
Mental Depression
|
0.600 |
Biomarker
|
disease |
BEFREE |
Serum S100B can be used as a biomarker of depression.
|
30745657 |
2020 |
Mental Depression
|
0.600 |
Biomarker
|
disease |
BEFREE |
Notably, ketamine increased the proliferation of NPCs independent of the NMDA receptor, while transcriptome analysis revealed significant upregulation of insulin-like growth factor 2 (IGF2) and p11, a member of the S100 EF-hand protein family, which are both implicated in the pathophysiology of depression, 24 h after ketamine treatment.
|
31554266 |
2019 |
Mental Depression
|
0.600 |
Biomarker
|
disease |
BEFREE |
Using a cohort of 86 pregnant women, we found that SSRIs significantly increase BDNF levels in late pregnancy and that S100B, but not BDNF, is associated with maternal depression in SSRI-treated women only.
|
30506371 |
2019 |
Mental Depression
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Patients with S100B levels in the intermediate tertile, that is, between 33 ng/L and 53 ng/L, had higher odds on remission, odds ratio: 5.5 (95%Confidence Interval (CI): 1.55-19.20, p = <0.01), and were more likely to remit from depression over time, hazard ratio: 1.96 (95%CI: 1.04-3.72, p = 0.04), compared with patients in the lowest tertile.
|
31493698 |
2019 |
Mental Depression
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
ANCOVA analysis followed by heteroscedasticity-consistent covariance matrix was performed to evaluate BDNF and S100B levels, adjusted for depression severity, pain levels and use of analgesics according different pathologies.
|
31100426 |
2019 |
Mental Depression
|
0.600 |
Biomarker
|
disease |
BEFREE |
EGb, as an adjunctive treatment, can effectively improve depressive symptoms and reduce expression of serum S100B, which is a marker of brain injury, suggesting that EGb restores neurologic function during the treatment of depression in elderly patients and S100B participates in the therapeutic mechanism.
|
30278520 |
2018 |
Mental Depression
|
0.600 |
Biomarker
|
disease |
BEFREE |
Alpha1-antitrypsin (A1AT), FAS, Heparin-binding EGF-like Growth Factor (HB-EGF), Insulin-like Growth Factor-1 (IGF-1), Luteinizing Hormone (LH), Macrophage Inflammatory Protein type 1 alpha (MIP-1α), Resitin, S100b, Tissue Inhibitor of Metalloproteinase type 1 (TIMP-1), and Vascular Cell Adhesion Molecule type 1 (VCAM-1) each were partial mediators of depression's association with δ.
|
28594820 |
2017 |
Mental Depression
|
0.600 |
Biomarker
|
disease |
RGD |
Brain-derived neurotrophic factor (BDNF) infusion restored astrocytic plasticity in the hippocampus of a rat model of depression.
|
21843601 |
2011 |
Mental Depression
|
0.600 |
Biomarker
|
disease |
PSYGENET |
Reversal of depressed behaviors in mice by p11 gene therapy in the nucleus accumbens.
|
20962330 |
2010 |
Mental Depression
|
0.600 |
Biomarker
|
disease |
PSYGENET |
Significant differences in the subgroup depression (first-episode and recurrent depression) were also shown in 3 genotypes of S100B rs9722 and rs11911834 in patients and control subjects (P < 0.05).
|
19497163 |
2009 |
Mental Depression
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Significant differences in the subgroup depression (first-episode and recurrent depression) were also shown in 3 genotypes of S100B rs9722 and rs11911834 in patients and control subjects (P < 0.05).
|
19497163 |
2009 |
Mental Depression
|
0.600 |
Biomarker
|
disease |
PSYGENET |
Although it may be open for discussion whether the neuroprotective effects of ONO-2506 are exclusively due to its inhibition of S100B synthesis, the latter action of ONO-2506 warrants studies of the effects of this drug in the pathobiology of depression.
|
16797859 |
2006 |
Mental Depression
|
0.600 |
Biomarker
|
disease |
BEFREE |
Although it may be open for discussion whether the neuroprotective effects of ONO-2506 are exclusively due to its inhibition of S100B synthesis, the latter action of ONO-2506 warrants studies of the effects of this drug in the pathobiology of depression.
|
16797859 |
2006 |
Mental Depression
|
0.600 |
Biomarker
|
disease |
PSYGENET |
S100 beta, a calcium binding brain protein expressed by astrocytes, has been shown to be involved in higher neural processes, including hippocampal-dependent behavioral traits and hippocampal neuronal long-term potentiation (LTP) and depression (LTD), neurophysiological phenomena that may be involved in exploring, learning and remembering novel stimuli.
|
8804639 |
1996 |